CAPR - カプリコ―ル・セラピュ―ティクス (Capricor Therapeutics Inc.) カプリコ―ル・セラピュ―ティクス

 CAPRのチャート


 CAPRの企業情報

symbol CAPR
会社名 Capricor Therapeutics Inc (カプリコ―ル・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ナイル・セラピューティクス(Nile Therapeutics Inc)は開発段階のバイオ医薬品会社であり、心不全を主とする心血管疾患を治療するための製品を開発する。同社は「Cenderitide」と「CU-NP」の2つの薬品候補を開発している。「Cenderitide」は、心不全を治療するキメラ性ナトリウム利尿ペプチドである。「CU-NP」は人体により生成されるアミノ酸チェーンと同一であるアミノ酸チェーン、特にC型ナトリウム利尿ペプチド(CNP)の環構造、及びウロジラチンのN-末端とC-末端で構成される合理的に設計された前臨床ナトリウム利尿ペプチドである。「Cenderitide」はメイヨー・クリニック(Mayo Clinic)の心臓・腎臓研究室の科学者に設計されている。「CU-NP」はメイヨー・クリニックにおける心臓・腎臓研究室の科学者に合理的に設計されたナトリウム利尿ペプチドである。   カプリコ―ル・セラピュ―ティクスは開発段階の米国のバイオ医薬品企業。心臓血管と腎臓疾患治療薬の研究、開発に注力する。心臓疾患治療向け新薬候補にはカ―ディオスフェアから得た同種異系細胞からなるCAP-1002、カ―ディオスフェアから得た自家細胞CAP-1002がある。   Capricor Therapeutics, Inc., is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy and the cytokine storm associated with COVID-19. Capricor is also investigating the field of extracellular vesicles and exploring the potential of exosome-based candidates to treat or prevent a variety of disorders. We are now developing two potential vaccines for COVID-19 as part of our exosome platform.
本社所在地 8840 Wilshire Blvd. 2nd Floor Beverly Hills CA 90211 USA
代表者氏名 Frank I. Litvack フランク・I・リヴァック
代表者役職名 Independent Executive Chairman of the Board
電話番号 +1 310-358-3200
設立年月日 35217
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 40人
url www.capricor.com
nasdaq_url https://www.nasdaq.com/symbol/capr
adr_tso
EBITDA EBITDA(百万ドル) -13.62626
終値(lastsale) 1.0441
時価総額(marketcap) 32104897.2552
時価総額 時価総額(百万ドル) 20.54025
売上高 売上高(百万ドル) 1.59310
企業価値(EV) 企業価値(EV)(百万ドル) 11.58228
当期純利益 当期純利益(百万ドル) 1.77510
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Capricor Therapeutics Inc revenues decreased 57% to $804K. Net loss increased 9% to $7.8M. Revenues reflect Collaboration income decrease from $1.4M to $0K. Basic Earnings per Share excluding Extraordinary Items increased from -$0.33 to -$0.28.

 CAPRのテクニカル分析


 CAPRのニュース

   Capricor Therapeutics to Present First Quarter 2022 Financial Results and Recent Corporate Update on May 10  2022/05/03 12:30:00 GlobeNewswire
Company to Host Conference Call, May 10, 2022, at 4:30 p.m. ET Company to Host Conference Call, May 10, 2022, at 4:30 p.m. ET
   Mid-Afternoon Market Update: Dow Drops 150 Points; Capricor Therapeutics Shares Plunge  2022/03/28 18:30:55 Benzinga
U.S. stocks traded mixed toward the end of trading, with the Dow Jones dropping around 150 points on Monday. The Dow traded down 0.43% to 34,709.71 while the NASDAQ rose 0.42% to 14,228.48. The S&P also fell, dropping, 0.02% to 4,542.04. Also check this: Alphabet And 3 Other Stocks Sold By Insiders Leading and Lagging Sectors Consumer discretionary shares jumped by 1.6% on Monday. Meanwhile, top gainers in the sector included Kaixin Auto Holdings (NASDAQ: KXIN ), up 31% and Newegg Commerce, Inc. (NASDAQ: NEGG ) up 41%. In trading on Monday, energy shares fell 2.8%. Top Headline Science Applications International Corp (NYSE: SAIC ) reported better-than-expected earnings for its fourth quarter. SAIC reported fourth-quarter FY22 revenue growth of 4% year-over-year to $1.78 billion and +1.4% organic, beating the consensus of $1.77 billion. Adjusted EPS of $1.50 beat the consensus of $1.23. SAIC sees revenue of $7.35 billion-$7.55 billion, lower than the consensus of $7.61 billion. It expects an Adjusted EPS of $6.80 -$7.10 …
   Capricor Shares Fall After Topline Results From Mid-Stage COVID-19 Trial  2022/03/28 16:06:09 Benzinga
Capricor Therapeutics Inc (NASDAQ: CAPR ) announced topline data from its Phase 2 INSPIRE study evaluating a single-dose intravenous infusion of CAP-1002 for hospitalized COVID-19 patients. Capricor said that the trial met its primary objective of safety. All efficacy endpoints were exploratory as the study was not powered to detect treatment differences. In the study of 63 randomized patients, 31% were admitted to the ICU before … Full story available on Benzinga.com
   Capricor Therapeutics COVID treatment meets safety objective in mid-stage trial  2022/03/28 13:16:46 Seeking Alpha
A phase 2 trial of Capricor Therapeutics (CAPR) COVID-19 treatment CAP-1002 met its primary objective of safety.
   Capricor Stops Work On Exosome-mRNA Based COVID-19 Vaccine Candidate  2022/03/11 18:29:45 Benzinga
In its Q4 FY21 earnings press release , Capricor Therapeutics Inc (NASDAQ: CAPR ) said it had halted work on the exosome-based jab due to the "current availability of vaccines for" COVID-19, Capricor said. Instead, the Company will focus its resources on CAP-1002 and announce the Lancet publication of Phase 2 trial results for the Duchenne muscular dystrophy (DMD) treatment CAP-1002. According to the Lancet publication, after … Full story available on Benzinga.com
   Thinking about buying stock in SoFi Technologies, Vinco Ventures, DiDi Global, Capricor Therapeutics, or ShiftPixy?  2022/01/25 15:45:00 Benzinga
NEW YORK , Jan. 25, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SOFI, BBIG, DIDI, CAPR, and PIXY. … Full story available on Benzinga.com
   Capricor jumps 12% after CAP-1002 commercialization deal in U.S. for treatment of DMD  2022/01/25 10:38:09 Seeking Alpha
Capricor Therapeutics (CAPR) soars 12.4% premarket after entering into a partnership with Nippon Shinyaku Co., Ltd., a Japanese pharmaceutical company, for the exclusive
   Analyzing Rallybio (NASDAQ:RLYB) and Capricor Therapeutics (NASDAQ:CAPR)  2021/12/14 10:18:44 Dakota Financial News
Rallybio (NASDAQ:RLYB) and Capricor Therapeutics (NASDAQ:CAPR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings and profitability. Analyst Ratings This is a breakdown of recent ratings and recommmendations for Rallybio and Capricor Therapeutics, […]
   Capricor Therapeutics provides key updates on its COVID-19 vaccine programs  2021/12/13 14:43:44 Seeking Alpha
   Muscular Dystrophy Treatment Market Future Business Opportunities 2021-2028 | Acceleron Pharma, Capricor Therapeutics, Bristol-Myers Squibb, Lexicon Pharmaceuticals  2021/12/11 05:30:58 OpenPR
Global Muscular Dystrophy Treatment Market has potentials to grow as the most influential market worldwide as it has been playing a noteworthy role in imprinting positive impacts on the international economy. The Global Muscular Dystrophy Treatment Market Report offers vital
   Capricor Therapeutics (CAPR) Scheduled to Post Quarterly Earnings on Tuesday  2021/11/04 14:32:41 Dakota Financial News
Capricor Therapeutics (NASDAQ:CAPR) is scheduled to issue its quarterly earnings data after the market closes on Tuesday, November 9th. Analysts expect the company to announce earnings of ($0.22) per share for the quarter. Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings results on Thursday, August 12th. The biotechnology company reported ($0.21) EPS for the quarter, []
   Dazzling stocks: Palantir Technologies Inc. (NYSE:PLTR -3.75%), Capricor Therapeutics, Inc. (NASDAQ:CAPR -12.25%)  2021/09/27 23:13:09 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Dazzling stocks: Palantir Technologies Inc. (NYSE:PLTR -3.75%), Capricor Therapeutics, Inc. (NASDAQ:CAPR -12.25%) appeared first on Stocks Equity .
   Thinking about buying stock in Naked Brand, Farmmi, Unique Fabricating, Aehr Test Systems, or Capricor Therapeutics?  2021/09/27 14:55:00 Benzinga
NEW YORK , Sept. 27, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NAKD, FAMI, UFAB, AEHR, and CAPR. Full story available on Benzinga.com
   Capricor Therapeutics Announces Another ''Final'' 12-Month P2 Duchenne Muscular Dystrophy Trial Result  2021/09/25 09:29:47 Seeking Alpha
   Capricor Stock Is Moving Higher As Duchenne Dystrophy Cell Therapy Slows Disease Progression By 71%  2021/09/24 13:28:42 Benzinga
Capricor Therapeutics Inc (NASDAQ: CAPR ) has announced final data from Phase 2 HOPE-2 trial of CAP-1002 for advanced stages of Duchenne muscular dystrophy (DMD). The trial met its primary efficacy endpoint of mid-level performance of upper limb (mid-PUL v1.2) and various skeletal and cardiac function endpoints. Young men in the advanced stages of DMD experienced improvements in skeletal and cardiac Full story available on Benzinga.com

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 カプリコ―ル・セラピュ―ティクス CAPR Capricor Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)